Yap, Timothy A.
Smith, Alan D.
Ferraldeschi, Roberta
Al-Lazikani, Bissan
Workman, Paul
de Bono, Johann S.
Article History
First Online: 22 July 2016
Competing interests
: All authors are current or former employees of The Institute of Cancer Research, London, UK, which has a commercial interest in the development of abiraterone acetate and phosphoinositide 3-kinase (PI3K) inhibitors, including pictilisib, and operates a rewards-to-discoverers scheme. T.A.Y. has received research funding from AstraZeneca and Vertex Pharmaceuticals; is or was a consultant or advisory board member for Pfizer and Merck Serono; and has received travel support from Bristol-Myers Squibb, Janssen and Merck. R.F. is an employee of Astex Pharmaceuticals. P.W. has received research funding from Astellas Pharma and Piramed Pharma, has ownership interest in Chroma Therapeutics and previously Piramed Pharma, and is or was a consultant or advisory board member for Chroma Therapeutics, Nextech Invest, NuEvolution and Piramed Pharma. J.S.d.B. has received consulting fees from Ortho Biotech Oncology Research and Development; consulting fees and travel support from Amgen, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Enzon, Exelixis, Genentech, GlaxoSmithKline, Medivation, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Supergen and Takeda; and grant support from AstraZeneca and Genentech.